Refractory IBS Patients React Well To Serum-Derived Bovine Immunoglobulin/Protein Isolate Therapy in Study

Refractory IBS Patients React Well To Serum-Derived Bovine Immunoglobulin/Protein Isolate Therapy in Study
shutterstock_81980782Entera Health, Inc. announced the publication of a study entitled “Serum-Derived Bovine Immunoglobulin/Protein Isolate Therapy for Patients with Refractory Irritable Bowel Syndrome” that reports the positive results obtained after oral administration of serum-derived bovine immunoglobulin/protein isolate in patients with irritable bowel syndrome who were unresponsive to therapeutics (referred to as refractory). The study was published in Open Journal of Gastroenterology. In this retrospective study, 35 patients with diarrhea-predominant irritable bowel syndrome (IBS-D) or alternating between constipation and diarrhea (IBS-M), all refractory to current therapies who were treated with serum-derived bovine immunoglobulin/protein isolate (SBI) were reviewed twice a day for the duration of the study. From these participants, 26 patients performed a lactose breath test (LBT) and were included for further analysis. LBT is a non-invasive procedure that helps physicians to test for the presence of bacteria in the small Intestine, which is also associated with irritable bowel syndrome. Patients within the positive LBT group (n=11) exhibited a 73% positive response to treatment with S
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *